


CLAIMS

1. A crystalline form of the compound of the formula (I)



(I)

characterized by a X-ray powder diffraction diagram at 25°C and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value $\pm$ 0.2°:

8,0

9,4

10,8

12,5

13,0

13,9

14,9

15,0

15,4

15,5

15,7

16,0

16,3

17,1

18,0

18,2

18,8

19,4

20,1

5	<u>20,3</u>
	<u>21,0</u>
	<u>21,5</u>
	<u>21,7</u>
	<u>23,0</u>
10	<u>23,4</u>
	<u>24,1</u>
	<u>24,4</u>
	<u>25,3</u>
	<u>25,4</u>
15	<u>25,8</u>
	<u>26,6</u>
	<u>27,1</u>
	<u>27,6</u>
	<u>28,4</u>
20	<u>28,8</u>
	<u>29,0</u>
	<u>29,8</u>
	<u>30,1</u>
	<u>30,3</u>
25	<u>31,1</u>
	<u>31,5</u>
	<u>31,8</u>
	<u>32,1</u>
	<u>32,4</u>
30	<u>33,0</u>
	<u>33,4</u>
	<u>33,8</u>
	<u>34,9</u>
	<u>35,2</u>
	<u>36,0</u>
	<u>37,0 and</u>
	<u>37,5</u>

selected from the group consisting of hydrate, anhydrate, and a mixture thereof.

2. ~~The form of the compound of claim 1, which is a hydrate of the compound of the formula (I).~~

3. ~~The form of the compound of claim 1 which is the hydrate characterized by a X ray powder diffraction diagram at 25°C and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value $\pm 0.2^\circ$: 9.4, 10.8, 15.0.~~

4. ~~The form of the compound of claim 1 which is the hydrate characterized by a X ray powder diffraction diagram at 25°C and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value $\pm 0.2^\circ$: 9.4, 10.8, 15.0, 16.0, 17.0.~~

5. ~~The form of the compound of claim 1 which is the hydrate characterized by a X ray powder diffraction diagram at 25°C and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value $\pm 0.2^\circ$: 9.4, 10.8, 15.0, 16.0, 17.0, 20.1, 22.9.~~

6. ~~The form of the compound of claim 1 which is the hydrate characterized by a X ray powder diffraction diagram at 25°C and with Cu-K alpha 1 as radiation source displaying at least the following reflections, quoted as 2Theta value $\pm 0.2^\circ$: 9.4, 10.8, 15.0, 16.0, 17.0, 20.1, 22.9, 24.3, 26.6, 29.8.~~

7.2. ~~A pharmaceutical composition comprising only one of the crystalline forms selected from the group comprising hydrate, anhydrate and formamide solvate of the compound of formula (I) as defined in claim 1 mainly and no significant fractions of another form of the compound of the formula (I).~~

8. ~~A pharmaceutical composition comprising a crystalline form of the compound of the formula (I) selected from the group consisting of hydrate, anhydrate, formamide solvate, amorphous form and a mixture thereof and further pharmaceutically acceptable excipients.~~

9. ~~The pharmaceutical composition of claim 8 comprising only the hydrate of the compound of the formula (I) mainly and no significant fractions of another form of the compound of the formula (I).~~

~~10.3.~~ The pharmaceutical composition of claim ~~8-2~~ comprising of the ~~hydrate of the compound~~ of the formula (I) as defined in claim 1 in more than 85 percent by weight related to the total amount of all forms of the compound of the formula (I) present in the composition.

~~11.4.~~ The pharmaceutical composition of claim ~~10-2~~ comprising of the ~~hydrate of the compound~~ of the formula (I) as defined in claim 1 in more than 90 percent by weight related to the total amount of all forms of the compound of the formula (I) present in the composition.

~~12.5.~~ A ~~crystalline~~ form of the compound of ~~any of claims 1 to 6~~ for use in the treatment and/or prophylaxis of neoplastic disorders, dermatological disorders, gynaecological disorders, cardiovascular disorders, pulmonary disorders, ophthalmological disorders, neurological disorders, metabolic disorders, hepatic disorders, inflammatory disorders, autoimmune disorders and pain.

~~13.6.~~ A ~~crystalline~~ form of the compound of ~~any of claims 1 to 6~~ for use in the treatment and/or prophylaxis of lymphoma, macular degeneration, psoriasis, lupus erythematosus, multiple sclerosis, COPD, gout, NASH, hepatic fibrosis, insulin resistance, metabolic syndrome, spondyloarthritis and rheumatoid arthritis, endometriosis and endometriosis-related pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia.

~~14.7.~~ A pharmaceutical composition of any of claims ~~7-2~~ to ~~11-4~~ for use in the treatment and/or prophylaxis of neoplastic disorders, dermatological disorders, gynaecological disorders, cardiovascular disorders, pulmonary disorders, ophthalmological disorders, neurological disorders, metabolic disorders, hepatic disorders, inflammatory disorders, autoimmune disorders and pain.

~~15.8.~~ A pharmaceutical composition of any of claims ~~7-2~~ to ~~11-4~~ for use in the treatment and/or prophylaxis of lymphoma, macular degeneration, psoriasis, lupus erythematosus, multiple sclerosis, COPD, gout, NASH, hepatic fibrosis, insulin resistance, metabolic syndrome, spondyloarthritis and rheumatoid arthritis, endometriosis and endometriosis-related pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia.

~~16.9.~~ Use of a compound as defined in ~~any of Claims 1 to 6~~ for the manufacture of a pharmaceutical composition for the treatment or prevention of neoplastic disorders, dermatological disorders, gynaecological disorders, cardiovascular disorders, pulmonary

disorders, ophthalmological disorders, neurological disorders, metabolic disorders, hepatic disorders, inflammatory disorders, autoimmune disorders and pain.

5 | ~~17.10.~~ Use of a compound as defined in ~~any of Claims 1 to 6~~ for the manufacture of a pharmaceutical composition for the treatment or prevention of lymphoma, macular degeneration, psoriasis, lupus erythematosus, multiple sclerosis, COPD, gout, NASH, hepatic fibrosis, insulin resistance, metabolic syndrome, spondyloarthritis and rheumatoid arthritis, endometriosis and endometriosis-related pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia.

10 | ~~18.11.~~ Use of a compound as defined in ~~any of Claims 1 to 6~~ for the manufacture of a stable pharmaceutical composition.